US 11,701,394 B2
Compositions and methods for treating cholestatic disease
Madhumitha Nandakumar, Arlington, MA (US); Alice Peiyu Liou, Somerville, MA (US); Elizabeth Moritz Halvorsen, Malden, MA (US); Gregory McKenzie, Arlington, MA (US); Edward J. O'Brien, Arlington, MA (US); and David Cook, Brookline, MA (US)
Assigned to Seres Therapeutics, Inc., Cambridge, MA (US)
Appl. No. 16/639,492
Filed by Seres Therapeutics, Inc., Cambridge, MA (US)
PCT Filed Aug. 14, 2018, PCT No. PCT/US2018/046769
§ 371(c)(1), (2) Date Feb. 14, 2020,
PCT Pub. No. WO2019/036510, PCT Pub. Date Feb. 21, 2019.
Claims priority of provisional application 62/545,298, filed on Aug. 14, 2017.
Prior Publication US 2021/0008128 A1, Jan. 14, 2021
Int. Cl. A61K 35/745 (2015.01); A61P 1/16 (2006.01); A61K 31/58 (2006.01)
CPC A61K 35/745 (2013.01) [A61K 31/58 (2013.01); A61P 1/16 (2018.01)] 17 Claims
 
1. A method of reducing a side effect of a treatment for a cholestatic disease or condition in a subject in need thereof, comprising administering to the subject a composition which comprises a first bacterial species and a second bacterial species, wherein the first bacterial species and the second bacterial species are not the same, wherein the first bacterial species and the second bacterial species are selected from: Alistipes finegoldii, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides sp_3_1_19, Bacteroides intestinalis, Bacteroides sp_20_3, Bacteroides caccae, Bacteroides faecis, Bacteroides sp_3_1_23, Bacteroides sp_D20, Bacteroides eggerthii, Barnesiella intestinihominis, Bifidobacterium pseudocatenulatum, Blautia schinkii, Blautia wexlerae, Blautia sp_M25, Blautia producta, Clostridiales sp_SM4_1, Clostridium lavalense, Clostridium innocuum, Clostridium asparagiforme, Clostridium spiroforme, Clostridium hylemonae, Clostridium sordellii, Clostridium sp_YIT_12069, Clostridium paraputrificum, Clostridium glycolicum, Clostridium ghonii, Clostridium lactifermentans, Clostridium viride, Clostridium sp_HGF2, Clostridium symbiosum, Clostridium scindens, Clostridium disporicum, Clostridium butyricum, Clostridium orbiscindens, Clostridium bolteae, Clostridium sp_7_2_43FAA, Collinsella aerofaciens, Coprobacillus sp_D7, Coprococcus comes, Coprococcus eutactus, Dorea longicatena, Dorea formicigenerans, Erysipelotrichaceae bacterium_3_1_53, Eubacterium sp_3_1_31, Eubacterium sp_WAL_14571, Eubacterium limosum, Eubacterium hallii, Eubacterium rectale, Eubacterium contortum, Gemmiger formicillis, Lachnospiraceae bacterium_2_1_58FAA, Lachnospiraceae bacterium_9_1_43BFAA, Lachnospiraceae bacterium_3_1_57FAA_CT1, Lachnospiraceae bacterium_5_1_57FAA, Lachnospiraceae bacterium_oral_taxon_F15, Lactobacillus acidophilus, Lactobacillus gasseri, Parabacteroides distasonis, Pseudoflavonifractor capillosus, Roseburia faecis, Ruminococcus obeum, Ruminococcus bromii, Ruminococcus lactaris, or Tannerella sp_6_1_58FAA, and wherein the first species, the second species, or both are capable of enhancing the efficacy of the treatment, such that the treatment can be administered to the subject at a lower dose, at reduced frequency, or both.